NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Mesenchymal. Here’s a post from May 13, 2022. Slightly edited.

flipper44
Member Level
Friday, May 13, 2022 12:55:07 AM

Right, so what background do we know about the comparison charts they gave us for the presentation on Tuesday?

Did you know?

1. People over 65 are MUCH more likely to have mesenchymal tumor signatures.
2. Patients with incomplete debulking are MUCH more likely to have remaining mesenchymal tumor signatures that are hypermutated particularly after chemo/radiation.
3. Patients that have a recurrence after chemo/radiation therapy are MUCH more likely to have mesenchymal tumor signatures that are hypermutated.
4. Hypermutated tumours are associated with MGMT promoter methylation.
5. As recently as February of this year, Dr. Liau still believed that this type of immunotherapy works best against Mesenchymal tumors with high mutation rate and methylated mgmt.
6. The reason you can’t do normal comparisons of the OS treatment arm to placebo is because the recurrent patients’ tumors were often turned into “Hot tumors” by the time they recurred treated with chemo/radiation and crossed-over to DCVax-l, and thus very susceptible DCVax-l in multiple instances.
7. Upon recurrence in the original treatment arm, patients that recurred often moved off study upon learning about doses remaining, if I recall correctly.

We need the publication to explain these things, so this treatment can get to patients.

This then would further resolve Ex’s paradox. Don’t blame Dr. Molholland for not drawing your attention to the above on Tuesday. Oddly, he had not known about some of the slides in the presentation until Tuesday morning.

I don’t know why retail was left so vulnerable on Tuesday, but please do not argue to shake out weak hands. Their hands have been diamonds for over a decade, so if anyone felt pressured to sell from that group, it’s unfair, imo.